Stockscreener 앱 받기
0.82
0.49%
0.004
시장 영업 전:
.79
-0.03
-3.66%
전일 마감가:
$0.816
열려 있는:
$0.7999
하루 거래량:
343.75K
Relative Volume:
0.61
시가총액:
$196.24M
수익:
-
순이익/손실:
$1.24B
주가수익비율:
0.0322
EPS:
25.475
순현금흐름:
$-31.80M
1주 성능:
-12.12%
1개월 성능:
-21.15%
6개월 성능:
-29.31%
1년 성능:
-8.02%
1일 변동 폭
$0.7826
$0.83
1주일 범위
$0.741
$0.975
52주 변동 폭
$0.66
$2.10
엔라이벡스 Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
0.82 | 195.28M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
엔라이벡스 Stock (ENLV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-02 | 재확인 | H.C. Wainwright | Buy |
엔라이벡스 주식(ENLV)의 최신 뉴스
Enlivex (ENLV) price target increased by 53.85% to 20.40 - MSN
Enlivex Therapeutics (ENLV) price target decreased by 30.00% to 7.14 - MSN
If You Invested $1,000 in Enlivex Ltd (ENLV) - Stock Titan
Volume Recap: Is now the right time to enter Enlivex Therapeutics Ltd2026 Earnings Impact & Community Consensus Stock Picks - baoquankhu1.vn
ENLV SEC FilingsEnlivex Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Enlivex Shares Tokenized on Ondo Global Markets to Expand Global Digital Investor Access - TipRanks
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares - The Manila Times
Ondo tokenizes Enlivex (Nasdaq: ENLV) shares for global digital access - Stock Titan
Ondo Global Markets Tokenizes Enlivex's Ordinary Shares - 富途牛牛
Rain Crypto Jump On Red Market: Big Pharma Enlivex Raised $21M Treasury - 99Bitcoins
ENLV Stock Rating: HC Wainwright & Co. Raises Price Target to $2 - GuruFocus
Enlivex shares jump after earnings as treasury gains boost results - MSN
ENLV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ENLV PE Ratio & Valuation, Is ENLV Overvalued - Intellectia AI
Enlivex clears pivotal FDA hurdle in knee osteoarthritis - Longevity.Technology
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Progress Index
Market Wrap: What analysts say about Enlivex Therapeutics Ltd stock2026 Big Picture & Technical Entry and Exit Tips - baoquankhu1.vn
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Enlivex Announces $21M Debt Financing and Prediction Markets Treasury Expansion - Bitcoin.com News
RAIN Token Climbs to 25th in Market Cap Following Institutional Activity and Protocol Upgrades - Bitget
Enlivex Therapeutics Tokenized Stock (Ondo) price today, ENLVon to USD live price, marketcap and chart - CoinMarketCap
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025 - NewMediaWire
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025 | Corporate - EQS News
Published on: 2026-03-26 22:45:56 - baoquankhu1.vn
Enlivex Reports Full-Year 2025 Results, Profit of $1.23 Billion and Diluted Earnings per Share of $25.48 - marketscreener.com
Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains - The Globe and Mail
Enlivex Highlights Rain’s AI Agent Launch and $5 Million Grant Program to Expand Prediction Markets - tipranks.com
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt - manilatimes.net
Enlivex (NASDAQ: ENLV) highlights Rain AI launch, $5M grants and RAIN token burn - Stock Titan
One prompt can now create a live prediction market as Rain adds $5M - Stock Titan
Enlivex Obtains $21 Million Loan to Purchase RAIN Tokens and Initiate $20 Million Buyback - Bitget
Earnings call transcript: Enlivex Q4 2025 sees stock surge on treasury gains - Investing.com Australia
Envilex Therapeutics (ENLV) Reports Strong FY GAAP EPS - GuruFocus
Enlivex Soars After FDA Approval for Allocetra Trial - StocksToTrade
Enlivex Stock Boosted by FDA Approval for Allocetra in Osteoarthritis Trials - timothysykes.com
Enlivex Therapeutics Q4 Earnings Call Highlights - marketbeat.com
Enlivex Allocetra Takes A Leap as FDA Clears Phase 2b Trial for Osteoarthritis - timothysykes.com
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 - Bitget
Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback - The Globe and Mail
Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS - MarketBeat
Enlivex Ltd. Reports $1.23 Billion Net Income for 2025 Driven by Treasury Asset Appreciation - Quiver Quantitative
엔라이벡스 (ENLV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):